Results of these studies showed that Cobimetinib, a MEK inhibitor, induces IFN-gamma-dependent MHC1 and PD-L1 upregulation on tumor cells, thus augmenting anti-tumor activity by enhancing intra-tumoral CD8+ T-lymphocyte activation and synergizing with immune checkpoint blockade [185, 186]. Here, MAP2K7 is linked to neoplasm.